FARON PHARMACEUTICALS OY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 127.5 GBX | 0.00% |
|
+8.51% | -58.20% |
| 16/04 | Faron Pharmaceuticals Oy Confirms Plans for the Coming Months | CI |
| 15/04 | Faron Pharmaceuticals reappoints former finance chief on interim basis | AN |
Chart calendar Faron Pharmaceuticals Oy
781daea.xkaIccOHxU2OM7C9FhpteK7ryVp2OhLHzfZS4XQDq5M.iiXKG4_GpD--cPjoemgDDpa-hW4HAnue-5chghUzwNmiI84X8srxI_Rx6Q~1f87e379c97eac4465b084c14cf5a355
Upcoming events on Faron Pharmaceuticals Oy
Past events on Faron Pharmaceuticals Oy
| 05/04/2024 12:30 pm | Annual General Meeting |
| 19/03/2024 02:30 pm | BEXMAB Phase I Study Results Call |
| 13/03/2024 05:30 pm | Q4 2023 Earnings Call |
| 13/03/2024 12:30 pm | Q4 2023 Earnings Release |
| 06/03/2024 | Carnegie Healthcare Conference |
| 25/01/2024 | Proactive One2One Investor Forum |
| 12/01/2024 01:30 am | JPMorgan Healthcare Conference |
| 11/12/2023 07:30 am | American Society of Hematology Meeting - Abstract No: 2915 |
| 11/10/2023 05:30 pm | BEXMAB Phase I/II Study Results Call |
| 22/09/2023 11:30 am | Extraordinary Shareholders Meeting |
| 12/09/2023 08:00 pm | H.C. Wainwright Global Investment Conference |
| 29/08/2023 05:30 pm | Q2 2023 Earnings Call |
| 29/08/2023 09:31 am | Q2 2023 Earnings Release |
| 10/08/2023 10:00 pm | Canaccord Genuity Growth Conference |
| 19/07/2023 06:00 pm | BEXMAB Phase I/II Study Results Call |
| 10/06/2023 03:30 am | European Hematology Association Hybrid Congress - Poster No: P542 |
| 08/06/2023 | European Hematology Association Hybrid Congress |
| 02/06/2023 | American Society for Clinical Oncology Meeting |
| 20/04/2023 05:30 pm | Canaccord Genuity Horizons in Oncology Virtual Conference |
| 18/04/2023 06:30 pm | American Association for Cancer Research Meeting - Abstract ID Section 37 Board 9 |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million EUR | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | 0,00 2,90 - | 0,00 0,00 - | 0,00 0,00 - | 14,4 |
|
EBITDA Million EUR | Released Forecast Spread | -12,9 -6,90 -86.42% | -16,4 -12,9 -26.91% | -20,8 -19,4 -7.22% | -27,1 -27,4 1% | -28,2 -27,4 -3.11% | -3,47 |
|
EBIT Million EUR | Released Forecast Spread | -13,1 -7,31 -79.22% | -16,7 -14,0 -18.96% | -21,1 -18,2 -15.98% | -27,4 -25,2 -8.69% | -28,6 -27,7 -3.32% | -3,73 |
|
Earnings before Tax (EBT) Million EUR | Released Forecast Spread | -13,3 -7,30 -81.52% | -16,9 -14,2 -19.27% | -21,2 -16,8 -26.06% | -28,7 -25,7 -11.94% | -30,9 -29,2 -5.88% | -5,70 |
|
Net income Million EUR | Released Forecast Spread | -13,3 -7,30 -81.67% | -16,9 -14,2 -19.34% | -21,2 -16,8 -26.15% | -28,7 -27,4 -5.05% | -30,9 -29,2 -5.88% | -6,37 |
|
EPS EUR | Released Forecast Spread | -0,31 -0,21 -47.62% | -0,37 -0,30 -23.33% | -0,42 -0,35 -20.74% | -0,52 -0,50 -4.83% | -0,48 -0,31 -54.84% | -0,31 |
| Announcement Date | 20/03/20 | 25/03/21 | 25/03/22 | 03/03/23 | 13/03/24 | - |
Quarterly results
| Fiscal Period | December | 2019 S2 | 2020 S1 | 2020 S2 | 2021 S1 | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 | 2025 S1 | 2025 S2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million EUR | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 | 0,00 | 0,00 | 0,00 |
|
EBITDA Million EUR | Released Forecast Spread | -6,57 -3,38 -94.32% | -7,02 -5,36 -30.88% | -9,36 -6,70 -39.64% | -10,3 -7,50 -37.09% | -13,2 -12,9 -2.43% | -13,9 | -12,6 | -15,6 -14,7 -6.38% | -13,9 | -15,7 | |||
|
EBIT Million EUR | Released Forecast Spread | -6,76 -3,60 -87.72% | -7,15 -5,51 -29.67% | -9,51 -6,80 -39.84% | -10,4 -7,70 -35.38% | -10,7 -6,30 -69.59% | -13,4 -12,2 -9.54% | -14,1 -10,7 -32.04% | -12,8 -13,8 6.82% | -15,8 -14,7 -6.94% | -14,1 | -15,9 | ||
|
Earnings before Tax (EBT) Million EUR | Released Forecast Spread | -6,84 -3,60 -90% | -7,34 -5,49 -33.75% | -9,59 -6,80 -41.07% | -10,6 -7,70 -37.06% | -10,6 -6,30 -68.65% | -13,1 -12,3 -6.96% | -15,6 -11,4 -37.09% | -13,7 -14,4 4.32% | -17,2 -15,8 -8.95% | -15,3 | -17,2 | ||
|
Net income Million EUR | Released Forecast Spread | -6,85 -3,60 -90.28% | -7,34 -5,49 -33.75% | -9,60 -6,80 -41.22% | -10,6 -7,70 -37.14% | -10,6 -6,30 -68.79% | -13,1 -12,3 -7.11% | -15,6 -13,6 -14.77% | -13,7 -15,6 11.99% | -17,2 -15,8 -8.95% | -15,3 | -17,2 | ||
|
EPS EUR | Released Forecast Spread | -0,16 -0,10 -60% | -0,16 -0,14 -14.29% | -0,22 -0,10 -120% | -0,21 -0,20 -5% | -0,21 -0,10 -110% | -0,25 -0,20 -25% | -0,27 -0,20 -35% | -0,22 -0,30 26.67% | -0,26 -0,21 -23.81% | -0,21 | -0,21 | ||
| Announcement Date | 20/03/20 | 24/09/20 | 25/03/21 | 26/08/21 | 25/03/22 | 25/08/22 | 03/03/23 | 29/08/23 | 13/03/24 | - | - | - | - |
More events
Past sector events for Faron Pharmaceuticals Oy
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- FARN Stock
- Calendar Faron Pharmaceuticals Oy
